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ABSTRACT Human infections with inﬂuenza viruses exhibit mild to severe clinical
outcomes as a result of complex virus-host interactions. Induction of inﬂammatory
mediators via pattern recognition receptors may dictate subsequent host responses
for pathogen clearance and tissue damage. We identiﬁed that human C-type lectin
domain family 5 member A (CLEC5A) interacts with the hemagglutinin protein of in-
ﬂuenza viruses expressed on lentiviral pseudoparticles through lectin screening. Si-
lencing CLEC5A gene expression, blocking inﬂuenza-CLEC5A interactions with anti-
CLEC5A antibodies, or dampening CLEC5A-mediated signaling using a spleen
tyrosine kinase inhibitor consistently reduced the levels of proinﬂammatory cyto-
kines produced by human macrophages without affecting the replication of inﬂu-
enza A viruses of different subtypes. Infection of bone marrow-derived macrophages
from CLEC5A-deﬁcient mice showed reduced levels of tumor necrosis factor alpha
(TNF-) and IP-10 but elevated alpha interferon (IFN-) compared to those of wild-
type mice. The heightened type I IFN response in the macrophages of CLEC5A-
deﬁcient mice was associated with upregulated TLR3 mRNA after treatment with
double-stranded RNA. Upon lethal challenges with a recombinant H5N1 virus,
CLEC5A-deﬁcient mice showed reduced levels of proinﬂammatory cytokines, de-
creased immune cell inﬁltration in the lungs, and improved survival compared to the
wild-type mice, despite comparable viral loads noted throughout the course of in-
fection. The survival difference was more prominent at a lower dose of inoculum.
Our results suggest that CLEC5A-mediated enhancement of the inﬂammatory re-
sponse in myeloid cells contributes to inﬂuenza pathogenicity in vivo and may be
considered a therapeutic target in combination with effective antivirals. Well-
orchestrated host responses together with effective viral clearance are critical for op-
timal clinical outcome after inﬂuenza infections.
IMPORTANCE Multiple pattern recognition receptors work in synergy to sense viral
RNA or proteins synthesized during inﬂuenza replication and mediate host responses
for viral control. Well-orchestrated host responses may help to maintain the inﬂam-
matory response to minimize tissue damage while inducing an effective adaptive
immune response for viral clearance. We identiﬁed that CLEC5A, a C-type lectin re-
ceptor which has previously been reported to mediate ﬂavivirus-induced inﬂamma-
tory responses, enhanced induction of proinﬂammatory cytokines and chemokines in
myeloid cells after inﬂuenza infections. CLEC5A-deﬁcient mice infected with inﬂu-
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enza virus showed reduced inﬂammation in the lungs and improved survival com-
pared to that of the wild-type mice despite comparable viral loads. The survival dif-
ference was more prominent at a lower dose of inoculum. Collectively, our results
suggest that dampening CLEC5A-mediated inﬂammatory responses in myeloid cells
reduces immunopathogenesis after inﬂuenza infections.
KEYWORDS C-type lectins, CLEC5A, spleen tyrosine kinase (Syk), inﬂuenza virus,
macrophages
Inﬂuenza viruses impact human health through annual epidemics, intermittent pan-demics, and sporadic zoonotic infections. Infection may lead to self-limited or severe
clinical symptoms as a result of complex virus-host interactions (1–5). Activation of
pattern recognition receptors (PRRs) that rapidly respond to invading pathogens or
damage-associated molecular patterns (DAMP) through induction of inﬂammatory
mediators may dictate the subsequent adaptive immune response for pathogen clear-
ance and clinical outcome. Various intracellular PRRs, including the Toll-like receptors
(TLR) 3, 7, and 10 (6–9), retinoic acid-inducible gene I (RIG-I) (10), or Nod-like receptors
NLRP3 and NOD2 (11–13), sense viral RNA or proteins produced during inﬂuenza virus
replication, leading to induction of an inﬂammatory response followed by activation of
CD4 or CD8 T cells (5, 14). Poorly coordinated host responses may pave the way for
severe clinical outcomes characterized by elevated inﬂammatory responses, increased
leukocyte inﬁltration, and pulmonary tissue injury (15–19).
Signaling through C-type lectin receptors (CLRs) may further modulate host defense
against infections by different microbes (20). The C-type lectin superfamily includes
soluble or integral proteins containing the characteristic C-type lectin-like domain
(CTLD) that binds to carbohydrates, lipids, or proteins (21). The integral CLRs on
myeloid cells can signal through the immunoreceptor tyrosine-based activation motif
(ITAM) or immunoreceptor tyrosine-based inhibition motif (ITIM) signaling motifs either
directly or in association with other adaptor proteins (21, 22) and trigger a plethora of
myeloid cell responses, such as phagocytosis (23), priming cytotoxic T lymphocytes
(24), respiratory burst (25), or production of proinﬂammatory cytokines (26, 27). Fur-
thermore, CLR signaling may antagonize or synergize the signals from other PRRs to
regulate the host immune response (21, 22).
Multiple soluble C-type lectins, such as mannose-binding lectin (MBL), surfactant
protein D (SP-D), and collectin kidney 1, possess neutralizing activity against inﬂuenza
virus during infection (28–30). Galectin-1 of the S-type lectin family and the serum
amyloid P of the pentraxin family have also been shown to ameliorate inﬂuenza
infectivity by inhibiting hemagglutinin (HA) activity (31, 32). In addition, CLRs expressed
on myeloid cells, including DC-SIGN, DC-SIGNR, macrophage mannose receptor (MMR),
and macrophage galactose-type lectin (MGL), can mediate inﬂuenza virus internaliza-
tion in a sialic acid-independent manner (33–36). However, it is not known if inﬂuenza
infections trigger signaling via myeloid CLRs that further modulate the host immune
response. Here, we identify that the spleen tyrosine kinase-coupled C-type lectin
domain family 5 member A (CLEC5A), which has previously been reported to mediate
ﬂavivirus-induced inﬂammatory response (26, 27, 37), enhanced induction of proin-
ﬂammatory cytokines and chemokines in myeloid cells after inﬂuenza A virus infection.
Blockade of CLEC5A-mediated signaling attenuated inﬂuenza virus-induced inﬂamma-
tory responses in macrophages without affecting viral replication. With reduced cyto-
kines but comparable viral loads in mouse lungs, the CLEC5A knockout (CLEC5A/)
mice were protected after lethal inﬂuenza challenge compared to C57BL/6 wild-type
(WT) mice, although a more prominent difference was observed when they were
challenged with a lower inoculum. This suggested that dampening CLEC5A-mediated
inﬂammatory responses in the myeloid cells is able to alleviate inﬂuenza pathogenicity
in vivo. Our results highlight the signiﬁcance of viral load control and a well-
orchestrated host response in inﬂuenza pathogenesis.
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RESULTS
Binding of inﬂuenza HA-expressing pseudotyped lentiviral particles to human
soluble CLEC5A. The hemagglutinin (HA) glycoproteins are abundantly present on the
surface of inﬂuenza virions and have been reported to interact with different CLRs to
facilitate viral entry through glycans synthesized during posttranslational modiﬁcations
(33–36). Differential inﬂammatory cytokine responses have been reported after infec-
tions with H5N1 and H1N1 inﬂuenza viruses (16, 38, 39). To investigate the potential
interactions between inﬂuenza virus and human CLRs, pseudotyped lentiviral particles
with surface expression of inﬂuenza HA proteins derived from an H5N1 isolate, A/Viet-
nam/1203/04 (PP-VNHA), or a seasonal H1N1 isolate, A/Hong Kong/54/98 (PP-HKHA),
were coincubated with a panel of soluble recombinant human CLR-Fc fusion proteins
precoated on 96-well plates. The functions of the HA proteins expressed by PP-VNHA
and PP-HKHA resemble the biological functions of those presented by inﬂuenza viruses
with hemagglutination activity to turkey red blood cells, and they mediate entry and
the transduction of renilla luciferase reporter in MDCK cells (data not shown). Pseu-
doparticles without surface glycoprotein expression were coincubated with soluble
recombinant human CLR-Fc fusion proteins as negative controls to determine the
background binding signals. The binding intensity of the HA-expressing pseudopar-
ticles to each CLR was normalized to the binding intensity to CLEC4L (DC-SIGN), which
is known to interact with inﬂuenza HA (33) (Fig. 1). CLEC4M (DC-SIGNR), CLEC7A,
CLEC4C, CLEC9A, and CLEC5A gave more than 50% binding signal relative to that of
CLEC4L for PP-VNHA,NA. The detection of a positive signal indicates that there is either
a direct interaction between the soluble CLR and the HA-expressing pseudoparticles or
that there is an indirect mediator bound to both the soluble CLR and the HA-expressing
pseudoparticles. For example, DC-SIGN is known to recognize the high-mannose
N-linked glycans present on inﬂuenza HA glycoprotein (33). CLEC5A was selected for
further investigation, as it gave the highest binding signal to the PP-VNHA virus
expressing H5 HA protein. CLEC5A activation by dengue virus (DV) or Japanese
encephalitis virus (JEV) induces DAP12 phosphorylation and mediates induction of
proinﬂammatory cytokines (tumor necrosis factor alpha [TNF-] and interleukin-6 [IL-6])
and chemokines (IP-10, MIP-1, monocyte chemoattractant protein 1 [MCP-1], and IL-8)
(26, 37, 40). Since hyperinduction of proinﬂammatory cytokines is a signature for H5N1
pathogenesis (16), we hypothesized that CLEC5A is involved in regulating the host
inﬂammatory response upon inﬂuenza virus infection.
CLEC5A enhanced proinﬂammatory response in human PBMC-derived macro-
phages after inﬂuenza virus infection. To study the CLEC5A-mediated host re-
sponse, human peripheral blood mononuclear cells (PBMCs) obtained from four
FIG 1 Identiﬁcation of CLEC5A as potential PRR for inﬂuenza virus. The relative binding intensity of the
pseudoparticles expressing inﬂuenza HA derived from H5N1 or H1N1 viruses to a panel of soluble human
CLRs is shown. Brieﬂy, 0.5 g of soluble human CLRs was coated on the plate, followed by incubation
with the HA-expressing pseudoparticles. The bound pseudoparticles were detected by anti-H5 or anti-H1
antibodies. The absorbance (Abs) obtained was normalized to the absorbance of CLEC4L. The dotted line
represents 50% binding signal compared to that of CLEC4L. The data shown are the means  standard
deviations (SD) from 8 replicates from 4 independent experiments.
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donors were each differentiated into macrophages and dendritic cells, and CLEC5A
surface expression was monitored. High levels of CLEC5A were detected on CD14/
major histocompatibility complex class II-positive (MHC-II) macrophages differen-
tiated with macrophage colony-stimulating factor (M-CSF) (M-M) (72.9%  8.9%)
or granulocyte-macrophage colony-stimulating factor (GM-CSF) (GM-M) (94.8% 
4.9%) but not on those differentiated with autologous serum (17.2%  11.4%) or on
the CD14/MHC-II dendritic cells differentiated with GM-CSF and IL-4 (11.9%  9.0%)
(data not shown). Short interfering RNA (siRNA)-mediated gene silencing was applied
to knock down CLEC5A expression in M-M and GM-M. Among the primary macro-
phages transfected with nontargeting control siRNA at 72 h posttransfection, 89.6% of
cells expressed CLEC5A on the cell surface; in comparison, 71.1% of the primary
macrophages transfected with the siRNA targeting human CLEC5A expressed CLEC5A.
Due to the inefﬁcient siRNA knockdown efﬁciency in primary macrophages, we pro-
ceeded to cell sorting after siRNA knockdown to yield CLEC5A and CLEC5A popu-
lations as described in Materials and Methods. Speciﬁcally, at 72 h after siRNA knock-
down followed by negative cell sorting, 79.4% of the M-M transfected with
nontargeting control siRNA (siNT) and 15.6% of the M-M transfected with CLCE5A-
speciﬁc siRNA (siCLEC5A) showed surface expression of CLEC5A. We observed that the
surface expression of CLEC5A was lowest at 72 h posttransfection and continued to
remain low at 96 h posttransfection (data not shown). As such, infections with inﬂuenza
viruses were performed at 72 h posttransfection with samples collected 24 h later (96
h posttransfection).
Previous studies from our laboratory have demonstrated differential proinﬂamma-
tory cytokine responses in human macrophages after infections with A/Vietnam/
1203/04 (H5N1) and A/HK/54/98 (H1N1) inﬂuenza viruses (38, 39). We hypothesized
that such differential cytokine responses are induced through interactions between
inﬂuenza surface glycoprotein and CLEC5A. The CLEC5A and CLEC5A M-M and
GM-M were infected with recombinant inﬂuenza viruses with identical internal genes
derived from the A/PR/8/34 virus but with different surface HA and NA glycoproteins
derived from the A/Hong Kong/54/98 (H1N1) (denoted HKHA,NA) and A/Vietnam/
1203/04 (H5N1) (denoted VNHA,NA) viruses based on the hypothesis that the interaction
between CLR and inﬂuenza virus was mediated via viral surface glycoproteins. After
infection with the VNHA,NA virus, the CLEC5A and CLEC5A cells showed comparable
M gene copies, suggesting that CLEC5A does not affect viral entry or replication in
M-M (Fig. 2A) or GM-M (Fig. 3A). However, signiﬁcantly lower levels of cytokines
(TNF-, alpha interferon [IFN-], and IL-6) and chemokines (IP-10, MIP-1, MCP-1, and
MIG) were detected in the CLEC5A M-M (Fig. 2B) or GM-M (Fig. 3B) than in the
CLEC5A cells (P values of 0.05 by Mann-Whitney test).
Compared to the H5N1 VNHA,NA virus, the H1N1 HKHA,NA virus showed lower
infectivity in the M-M (Fig. 2A) and GM-M (Fig. 3A) and induced lower levels of
proinﬂammatory cytokines in M-M (Fig. 2B) and GM-M (Fig. 3B). Infection of HKHA,NA
virus in CLEC5A and CLEC5A cells showed comparable M gene copies in M-M (Fig.
2A) or GM-M (Fig. 3A); however, reduced levels of IP-10, MCP-1, TNF-, and IFN- were
observed from the CLEC5AM-M (Fig. 2B) or GM-M (Fig. 3B) than the CLEC5A cells,
although the level of reduction was not as obvious as that observed for the VNHA,NA
virus. IL-4, IL-10, IL-12p70, and transforming growth factor beta (TGF-) were under the
detection limit. Overall, the results suggest that CLEC5A mediates enhanced inﬂamma-
tory responses in M-M and GM-M after infection with the recombinant H5N1 or
H1N1 inﬂuenza viruss.
Enhanced inﬂammatory response mediated by CLEC5A is subtype indepen-
dent. We further applied wild-type A/Hong Kong/54/98 (H1N1), A/Vietnam/1203/04
(H5N1), and A/Shanghai/2/13 (H7N9) viruses to assess if the enhanced inﬂammatory
response mediated by CLEC5A would be affected by different inﬂuenza strains that
differed by the gene constellations in all eight-gene segments. The H5N1 virus showed
the highest infectivity, followed by the H7N9 and H1N1 viruses in human M-M (Fig.
4A). H5N1 virus induced higher levels of TNF- and IFN- in the infected M-M (Fig. 4B),
Teng et al. Journal of Virology
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but the levels of chemokines (IP-10 and MCP-1) were comparable after infection with
H1N1, H5N1, or H7N9 viruses. Despite possessing different infectivity, all three viruses
showed comparable infectivity in CLEC5A and CLEC5A populations (Fig. 4A), further
supporting that the CLEC5A cells did not affect viral entry or replication in M-M.
Silencing of CLEC5A signiﬁcantly reduced the level of TNF- in H5N1-infected M-M
and the levels of IFN-, IP-10, and MCP-1 in M-M infected by H5N1, H7N9, or H1N1
viruses (Fig. 4B). Overall, these results suggest that CLEC5A mediates proinﬂammatory
cytokine and chemokine induction in human PBMC-derived macrophages independent
of the inﬂuenza virus subtypes.
Blocking CLEC5A-mediated signaling reduced inﬂammatory response in M-M
after inﬂuenza infection. CLEC5A mediates inﬂammatory responses through associ-
ation with the ITAM-containing DAP12 or the YINM-containing DAP10 adaptor proteins,
followed by spleen tyrosine kinase (Syk) or phosphoinositide 3-kinase (PI3K)-mediated
signaling pathways (22, 26, 27, 40, 41). Since Syk-mediated signaling was critical for
CLEC5A-induced lethal shock in mice (41) and inﬂammasome activation in DV patho-
genesis (27), we asked if Syk-mediated signaling is involved in the release of proin-
ﬂammatory cytokines after inﬂuenza infection. To address this question, M-M were
incubated with the selective Syk inhibitor Bay 61-3606 (42) 1 h prior to and throughout
FIG 2 CLEC5A mediates enhanced proinﬂammatory cytokine and chemokine induction in human M-M
after inﬂuenza virus infection. M-M differentiated from the PBMC of 8 independent donors were
transfected with CLEC5A gene-speciﬁc or nontargeting siRNA, followed by cell sorting to obtain the
CLEC5A-positive (CLEC5A_pos) and CLEC5A-negative (CLEC5A_neg) populations. The macrophages were
then infected with HKHA,NA or VNHA,NA recombinant viruses at an MOI of 2 for 24 h to determine viral M
gene copy numbers in infected M-M and viral titers in culture supernatants (log10 TCID50/ml in MDCK
cells) (A) and proinﬂammatory cytokines and chemokines in culture supernatant (means  SD, in pg/ml)
(B). P values from Mann-Whitney tests are shown.
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the course of infection with HKHA,NA or VNHA,NA viruses. The concentrations of IP-10 and
TNF- were reduced under increasing concentrations of Bay 61-3606 (Fig. 5A), while the
viral M gene copies remained unaffected (data not shown). We further asked if
blockade of the inﬂuenza virus-CLEC5A interaction is able to reduce proinﬂammatory
cytokine induction in human macrophages. Panels of antagonizing mouse anti-human
CLEC5A antibodies (clones 3E12A2, 3E12C1, 6E11A8, and 8H8F5) previously shown to
block DV- or JEV-induced proinﬂammatory cytokine releases from human macrophages
(26, 27, 37) were preincubated with M-M 1 h prior to and throughout the course of
infection with VNHA,NA virus. We found that clones 8H8F5 and 3E12A2 inhibit IP-10
secretion from M-M after VNHA,NA virus infection (Fig. 5B) in a dose-dependent
manner (Fig. 5C). The anti-CLEC5A blocking antibodies had no impact on inﬂuenza
replication, as the M gene copies detected in the M-M were comparable to those of
the isotype control-treated macrophages. Overall, these observations further support
the role of CLEC5A in mediating induction of proinﬂammatory cytokines in human
macrophages after inﬂuenza infection.
To further examine if binding of inﬂuenza virus to CLEC5A expressed on the cell
surface is sufﬁcient to trigger the proinﬂammatory cytokine or chemokine induction,
CLEC5A and CLEC5A M-CSF macrophages were infected with live or UV-inactivated
VNHA,NA viruses (UV-VNHA,NA) at a multiplicity of infection (MOI) of 2. The UV-VNHA,NA
virus still possessed hemagglutination activity to turkey red blood cells (data not
shown) but lacked infectivity, as the M gene copy numbers remained low at 24 h
postinfection compared to those of live VNHA,NA (Fig. 5D). Minimal induction of
cytokines was observed in CLEC5A and CLEC5A M-M after infection with the
UV-VNHA,NA virus (Fig. 5D). Similar results were observed when the MOI was increased
from 2 to 20 (data not shown). This observation is in accord with our previous
FIG 3 CLEC5A mediates enhanced proinﬂammatory cytokine and chemokine induction in human
GM-M after inﬂuenza virus infection. GM-M differentiated from the PBMC of 2 independent donors
were transfected with CLEC5A gene-speciﬁc or nontargeting siRNA, followed by cell sorting to obtain the
CLEC5A-positive (CLEC5A_pos) and CLEC5A-negative (CLEC5A_neg) populations. The macrophages were
then infected with HKHA,NA or VNHA,NA recombinant viruses at an MOI of 2 for 24 h to determine viral M
gene copy numbers in infected GM-M and viral titers in culture supernatant (log10 TCID50/ml in MDCK
cells) (A) and proinﬂammatory cytokines and chemokines in culture supernatants (means SD, in pg/ml)
(B). P values from Mann-Whitney tests are shown.
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observation that UV-inactivated DV is less potent than live DV to activate CLEC5A (26),
and active viral replication is required for the CLEC5A-mediated enhancement of the
inﬂammatory response in M-M.
Inﬂuenza infections in bone marrow-derived macrophages of CLEC5A/ mice
showed reduced levels of TNF- and IP-10 but increased IFN- compared WT
mice. CLEC5A/mice with deletion of exons 3 to 5 of the murine Clec5a genomic DNA
(37) and the genetically matched WT mice were applied to evaluate the impact of
CLEC5A on inﬂuenza pathogenesis. We ﬁrst characterized the inﬂammatory response of
bone marrow-derived macrophages (BMM) from CLEC5A/ or WT mice after treat-
ment with zymosan (Zy; TLR2 agonist), poly(I·C) (PIC; TLR3 agonist), lipopolysaccharide
(LPS; TLR4 agonist), or gardiquimod (GRD; TLR7 agonist). The levels of TNF- were
comparable between BMM derived from CLEC5A/ and WT mice after treatment
with PIC, LPS, GRD, or Zy (Fig. 6A). However, BMM from CLEC5A/ mice showed an
increased type I interferon response compared to that of the WT mice after PIC
treatment (Fig. 6A). In addition, reduced IP-10 was detected from the macrophages
derived from the CLEC5A/ mice after treatment with PIC or Zy.
BMM derived from CLEC5A/ or WT mice were infected with VNHA,NA virus at an
MOI of 2, and the levels of cytokines and chemokines from the culture supernatant
were determined at 24 h postinfection. The VNHA,NA virus showed comparable infec-
tivity in BMM derived from CLEC5A/ or WT mice. As observed in the CLEC5A human
M-M, reduced levels of TNF- and IP-10 (P  0.063 and P  0.046, respectively) were
detected in BMM of CLEC5A/ mice compared to those in the WT mice after infection
(Fig. 6B). Interestingly, a higher level of IFN- was detected in the CLEC5A/mice (P
0.001). The higher induction of the type I interferon response in the BMM derived from
the CLEC5A mice was associated with upregulated TLR3 mRNA after inﬂuenza virus
infection or PIC treatment (Fig. 6C). Overall, BMM derived from CLEC5A/ mice
showed reduced TNF- and IP-10 but increased IFN- compared to the WT mice after
infection with the VNHA,NA virus or treatment with PIC. The increased IFN- after
inﬂuenza infection could be related to the upregulation of TLR3 mRNA in CLEC5A/
FIG 4 CLEC5A-mediated proinﬂammatory response in human M-M after infections with inﬂuenza
viruses of H1N1, H5N1, and H7N9 subtypes. Human M-M differentiated from PBMC of 2 independent
donors were infected with A/Hong Kong/54/98 (H1N1), A/Vietnam/1203/04 (H5N1), or A/Shanghai/2/13
(H7N9) inﬂuenza viruses at an MOI of 2 for 24 h to determine viral M gene copy numbers in infected
M-M (A) and proinﬂammatory cytokines and chemokines in culture supernatants (means  SD, in
pg/ml) (B). P values from Mann-Whitney tests are shown.
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FIG 5 Blocking CLEC5A-mediated signaling with Syk inhibitor (Bay 61-3606) and CLEC5A antagonizing
antibodies reduced inﬂammatory response in human M-M after inﬂuenza virus infection. (A) Human
M-M differentiated from the PBMC of 3 independent donors were treated with dimethyl sulfoxide or
the Syk inhibitor Bay 61-3606 prior to and throughout the course of infection with HKHA,NA or VNHA,NA
virus at an MOI of 2 to determine the TNF- and IP-10 concentrations (means  SD, in pg/ml) from
culture supernatants at 24 h postinfection. (B) Human M-M differentiated from the PBMC of 4
independent donors were incubated with 1 g/ml of murine IgG1 isotype control antibody (Iso ctrl) or
clones of anti-human CLEC5A antibodies, which were previously shown to possess antagonizing activity
against DV or JEV infections, prior to and throughout the course of infection with VNHA,NA virus at an MOI
of 2 to determine the level of IP-10 (means  SD, in pg/ml) from culture supernatants at 24 h
postinfection. (C) Human M-M differentiated from the PBMC of 4 independent donors were incubated
with increasing concentrations of murine IgG1 isotype control antibody or the anti-CLEC5A antibody
(clone 8H8F5) prior to and throughout the course of infection with VNHA,NA virus at an MOI of 2 to
determine the level of IP-10 (means  SD, in pg/ml) from culture supernatants at 24 h postinfection. ns,
not signiﬁcant. (D) M-M differentiated from the PBMC of 2 independent donors were transfected with
CLEC5A gene-speciﬁc or nontargeting siRNA followed by cell sorting to obtain the CLEC5A-positive
(CLEC5A_pos) and CLEC5A-negative (CLEC5A_neg) populations. M-M were infected with VNHA,NA or
UV-inactivated VNHA,NA (UV-VNHA,NA) at an MOI of 2. Viral M gene copy numbers and levels of TNF- and
IP-10 (means SD, in pg/ml) in culture supernatant were determined at 24 h postinfection. P values from
Mann-Whitney tests are shown.
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mice, as observed after PIC treatment. The differential type I IFN response in human and
murine macrophages suggests that there are different levels of cross talk between
CLEC5A-mediated signaling and other cases of PRR-mediated signaling in these two
species.
CLEC5A/ mice with reduced inﬂammatory responses but lung viral loads
comparable to those of the WT mice were only moderately protected after lethal
inﬂuenza challenge. We further determined the impact of CLEC5A on inﬂuenza
pathogenesis in CLEC5A/ and WT mice after lethal challenge with 5 50% murine
lethal doses (MLD50) (4,766 PFU/mice) of the VNHA,NA virus. On days 1, 4, and 7, mouse
lungs were collected to determine the viral titers and levels of cytokines and chemo-
kines. Lower levels of TNF-, IFN-, IFN-, IP-10, MIP-1, and MCP-1 were observed in
lung homogenates of CLEC5A/ mice on day 7 postinfection (Fig. 7A) in spite of
comparable lung titers in the CLEC5A/ and WT mice on days 1, 4, and 7 postinfection
(Fig. 7B). Corroborated with the proinﬂammatory cytokine and chemokine levels in lung
homogenates, signiﬁcantly lower numbers of cells were noted in the bronchoalveolar
lavage (BAL) ﬂuid collected from the CLEC5A/mice compared to the WT mice on day
7 postinfection (Fig. 7C) but not on day 3 postinfection. Speciﬁcally, signiﬁcantly lower
numbers of B cells, CD8 T cells,  T cells, and NK cells were noted in the CLEC5A/
mouse lungs (Fig. 7D). The reduced number of CD8 T cells and NK cells correlated with
the lower IFN- concentration detected in the CLEC5A/ mouse lungs at day 7
FIG 6 (A) Inﬂammatory response in BMM derived from CLEC5A/ or WT mice after incubation with TLR
agonists or after inﬂuenza infection. BMM derived from CLEC5A/ or WT mice were treated with
gardiquimod (GRD; 10 g/ml), lipopolysaccharide (LPS; 100 ng/ml), poly(I·C) (PIC; 50 g/ml), or zymosan
(Zy; 10 g/ml) for 24 h to determine the level of cytokines and chemokines in the supernatant (means 
SD, in pg/ml, derived from 6 replicates of BMM obtained from 2 mice). (B) BMM derived from CLEC5A/
or WT mice were infected with VNHA,NA at an MOI of 2 for 24 h to determine the levels of cytokines and
chemokines in the supernatant (means  SD, in pg/ml, derived from 9 replicates of BMM obtained from
3 mice). (C) Copy number of TLR3 mRNA in BMM after activation with TLR agonist or inﬂuenza infection
at an MOI of 2 for 24 h (means  SD from 4 replicates of BMM obtained from 2 mice). P values from
Mann-Whitney tests are shown.
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postinfection. Histopathology examination also revealed reduced cell inﬁltration in the
CLEC5A/ (Fig. 7E) compared to the WT (Fig. 7F) mouse lungs at day 7 postinfection.
Despite the differences in lung inﬂammatory responses on day 7 postinfection, com-
parable weight loss was observed in both WT and CLEC5A/ mice (Fig. 7G). A
marginally higher survival rate was observed in CLEC5A/ mice (4/23, 17.4%) com-
pared to wild-type mice (1/25, 4%) (Fig. 7H) (P  0.014 by log-rank test). We observed
a more prominent cytokine reduction in the mouse lungs (Fig. 7A) than that observed
in BMM (Fig. 6B) derived from CLEC5A/ and WT mice after inﬂuenza infection,
possibly due to the mixed cell types present in the mouse lungs.
At a lower dose of inoculum (953.2 PFU/mouse, or 1 MLD50/mouse), the difference
in survival was more prominent, as 90% (9/10) of the CLEC5A/ mice survived the
lethal challenge compared to 40% (4/10) of the matching wild-type mice (Fig. 8A).
While there was no difference in mouse weight change (Fig. 8B) or lung viral titers
FIG 7 Lower levels of proinﬂammatory cytokines and reduced level of immune cell inﬁltration in the lungs of CLEC5A/ mice compared to the WT mice after
lethal challenge of 5 MLD50 of VNHA,NA virus. WT and CLEC5A/ mice were infected with 5 MLD50 of VNHA,NA intranasally; mouse lungs were collected at days
1, 4, and 7 postinfection (n  5 or 6 per group at each time point) to determine the concentrations of cytokines and chemokines (means  SD, in pg/ml) (A)
and virus titers (means  SD, in log10 TCID50/ml) (B). (C and D) BAL ﬂuid was collected from WT and CLEC5A/ mice (n  10 per group at each time point)
to monitor the total cell count (means  SD) detected on days 3 and 7 postinfection (C) and the immunophenotyping result on day 7 postinfection using
surface markers (P values from Mann-Whitney tests are shown) (D). Hematoxylin and eosin staining of the CLEC5A/ (E) and WT (F) mouse lungs at day 7
postinfection with 5 MLD50 of VNHA,NA (n  2 per group). (G and H) Changes in body weight (G) and survival (H) of WT and CLEC5A/ mice after challenge
with 5 MLD50 (P value from log-rank test is shown).
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(Fig. 8C), signiﬁcantly lower proinﬂammatory cytokine levels were observed in the
CLEC5A/ mouse lungs on day 4 (IP-10, IL-1, MCP-1, IFN-, MIP-1, and MIP-1), or
day 7 (TNF-, IFN-, and MIP-1) postinfection (Fig. 8D). Compared to the cytokine
levels detected in the CLEC5A/ and WT mice after infection with 5 MLD50 (Fig. 7A),
we noted an earlier reduction of the proinﬂammatory cytokines and chemokines in the
CLEC5A/mice than the WT mice (Fig. 8D). Since CLEC5A is restricted to myeloid cells,
reducing the dose of inoculation allowed us to better assess the potential proinﬂam-
matory role of CLEC5A, as inoculation at a higher dose may lead to substantial
replication and induction of proinﬂammatory cytokines in the epithelial cells where the
virus replicated equally well in both the CLEC5A/ and WT mouse lungs. These results
also suggest that early reduction of the proinﬂammatory response is associated with a
better survival outcome (as seen with the low-dose challenge). Overall, the data
support that CLEC5A mediates induction of proinﬂammatory cytokine myeloid cells
that may lead to differential immune cell inﬁltration to the lungs and tissue damage.
FIG 8 CLEC5A/ mice were protected from the sublethal challenge of VNHA,NA virus by reducing the
level of proinﬂammatory cytokine in the lungs. WT and CLEC5A/ mice were infected with 1 MLD50 of
VNHA,NA intranasally. Mouse survival (A) and body weight changes (B) were monitored every other day;
P values from log-rank tests are shown. (C and D) Viral titer (means  SD, in log10 TCID50/ml) (C) and
cytokine and chemokine levels (means  SD, in pg/ml) (D) detected in the mouse lungs at day 1, 4, and
7 postinfection (n  4 per group at each time point); P values from Mann-Whitney tests are shown.
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DISCUSSION
A series of complex virus-host interactions determine the clinical outcome of
inﬂuenza infections. Here, we report the identiﬁcation and validation of CLEC5A as a
PRR on myeloid cells that mediates enhanced inﬂammatory responses after inﬂuenza
virus infection. In human M-M or GM-M, we demonstrated that knocking down
CLEC5A expression by gene silencing, blocking inﬂuenza-CLEC5A interactions with
anti-CLEC5A antibodies, or dampening CLEC5A-mediated signaling using a Syk inhib-
itor consistently reduced levels of proinﬂammatory cytokines without affecting the
replication of inﬂuenza viruses of different subtypes. In murine BMM, reduced IP-10 but
elevated IFN- levels were observed in cells derived from the CLEC5A/ compared to
the WT mice after inﬂuenza infection. Upon lethal challenges at 5 MLD50 or 1 MLD50,
CLEC5A/ mice with reduced inﬂammatory response and immune cell inﬁltration in
the lungs showed signiﬁcantly improved survival compared to the WT mice, despite
comparable lung viral loads between the CLEC5A/ and WT mice throughout the
course of infections. The survival difference between the WT and CLEC5A/ mice was
more prominent when challenged at a lower lethal dose. Overall, we demonstrated
that dampening the CLEC5A-mediated proinﬂammatory cytokine response in myeloid
cells may lower the excessive inﬂammatory response and improve survival after inﬂu-
enza infections. The results highlight the Syk-coupled CLEC5A signaling pathway as a
potential target for immunomodulators to alleviate proinﬂammatory response associ-
ated with inﬂuenza immunopathogenesis.
CLEC5A has been demonstrated to mediate inﬂammatory responses in human or
murine macrophages upon DV or JEV infection (26, 37). DV mainly targets monocytes
for viral replication, and macrophages are considered a major source of proinﬂamma-
tory cytokine induction during the course of infection (26). Blocking DV-CLEC5A
interaction with intravenous injection of anti-CLEC5A blocking antibodies signiﬁcantly
dampened the serum levels of proinﬂammatory cytokines in DV2-infected STAT1/
mice and provided protection against DV2-induced complications, including hemor-
rhage and plasma leakage, leading to a better survival rate compared to the isotype
control antibody-treated mice (26). While inﬂuenza can similarly activate CLEC5A-
mediated inﬂammatory responses in the myeloid cells, inﬂuenza viruses predominantly
replicate at the respiratory epithelium cells. In addition, the mechanisms of inﬂuenza
virus or ﬂavivirus interaction with CLEC5A may differ, since some of the anti-CLEC5A
blocking antibodies previously shown to successfully dampen cytokine induction after
DV or JEV infection failed to suppress the secretion of IP-10 in M-M after inﬂuenza
virus infection (Fig. 5B). This suggests that the active binding site of CLEC5A for
inﬂuenza virus is different from that for DV or JEV. The binding sites for the anti-CLEC5A
antibodies capable of suppressing cytokine induction after DV, JEV, and inﬂuenza virus
infection should be further investigated to understand the nature of the ligands for
CLEC5A activation.
The cytokine proﬁles between human PBMC-derived macrophages and murine
BMM after inﬂuenza infections do not match fully, which could be due to differences
in CLEC5A-mediated signaling or differential cross talk with other signaling pathways in
these two species. Interspecies differences in the transcriptional response in human and
murine macrophages after TLR4-mediated LPS stimulation have been reported (43); in
addition, the inducible nitric oxide synthase (iNOS) gene can be induced by IFN- and
LPS stimulation in murine macrophages but not in human macrophages (44). These
studies suggest that despite signiﬁcant evolutionary conservation in the pattern rec-
ognition receptors, differences in the downstream gene expression proﬁle between
mouse and human can still be observed. We examined available literature aiming to
understand the impact of CLEC5A-mediated activation on cytokine production in
murine BMMs. Activation of CLEC5A in a murine 32Dcl3 myeloid precursor cell line with
agonist antibodies was reported to induce higher mRNA levels of RANTES, IP-10, and
CCL22 but not TNF- (45). This is consistent with our observation that the CLEC5A/
BMMs secreted signiﬁcantly lower levels of IP-10 but not TNF- than the CLEC5A
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BMMs after inﬂuenza infection. However, we observed a differential IFN- response
triggered in human and murine macrophage after inﬂuenza infection, which could be
due to differential cross talk between CLEC5A-mediated signaling and other signaling
pathways in human and murine macrophages after inﬂuenza infection. It is also not
known if functional compensation occurs in the CLEC5A knockout mice. Regardless of
the differential cytokine proﬁles exhibited in human macrophages and murine BMM
after inﬂuenza infections, the proinﬂammatory role of CLEC5A is consistently shown in
both species with different experimental results, including the reduction of proinﬂam-
matory cytokines in the macrophages or in the mouse lungs. Further studies are
needed to investigate CLEC5A-mediated signaling and the potential cross talk with
other signaling pathways in these two species.
Multiple PRRs work in synergy to detect viral RNA or proteins synthesized during
inﬂuenza replication (46–48). A well-orchestrated host response may help to maintain
the inﬂammatory response while inducing an effective adaptive immune response for
viral clearance. We observed survival advantage in CLEC5A/ mice after lethal inﬂu-
enza challenge, while a more prominent survival advantage was observed at a sublethal
dose. This is consistent with a report showing that mice deﬁcient in TLR3 showed
variable survival compared to WT mice depending on the dose or strain of inﬂuenza
virus used for challenge (49, 50). The more prominent survival advantage for the
CLEC5A/ mice over the WT mice at a lower dose of inoculum suggests that in
addition to the proinﬂammatory response elicited in the myeloid cells, viral replication
kinetics in the lung epithelium cells and the subsequent release of cytokines from the
infected cells also determine the survival outcome. The reduction of proinﬂammatory
cytokine secreted by CLEC5A-expressing monocytes/macrophages recruits lower num-
bers of NK, B, and T cells to the site of infection, which likely lead to reduced lung
damage and eventually increased mouse survival.
Taken together, we identiﬁed the Syk-coupled CLEC5A as a PRR for inﬂuenza virus
that mediates proinﬂammatory responses in human and murine myeloid cells. Without
affecting viral load, dampening CLEC5A-mediated inﬂammatory responses in myeloid
cells provided survival advantage in vivo while reducing NK, B, and T cell inﬁltration into
and tissue damage of the mouse lungs. Our results highlight the Syk-coupled CLEC5A
signaling pathway as a potential target for immunomodulators to alleviate proinﬂam-
matory responses associated with inﬂuenza immunopathogenesis.
MATERIALS AND METHODS
Generation of pseudoparticles expressing inﬂuenza HA. Pseudoparticles expressing inﬂuenza HA
were produced as described previously (51). Brieﬂy, the coding sequences of HA derived from VN1203
(H5N1) (PP-VNHA) or HK5498 (H1N1) (PP-HKHA) were cloned into the pcDNA3.1 vector (Invitrogen) with
an 8-amino-acid FLAG peptide (DYKDDDDK) added to the HA C terminus. Lentiviral packaging vector
plasmid pNL Luc E R, which encodes an HIV-1 provirus lacking a functional env gene and carries a
ﬁreﬂy luciferase reporter gene in place of the nef gene (provided by Pierre Charneau, Institute Pasteur,
Paris), were cotransfected with pcDNA3.1 with or without coding inﬂuenza HA sequence in 293T human
embryonic kidney cells using a CalPhos mammalian transfection kit (Clontech). Neuraminidase (5 mU/ml)
derived from Vibrio cholerae (Roche) was added to the medium at 36 h posttransfection. The culture
medium was harvested at 72 h posttransfection and was further concentrated by sucrose gradient.
Enzyme-linked immunosorbent assay (ELISA) using soluble human CLR and pseudoparticles
expressing inﬂuenza HA. Soluble CLRs were produced as described previously (26). CLRs were diluted
using dilution buffer (1% polyvinyl alcohol, 2 mM MgCl2, 2 mM CaCl2 in Tris-buffered saline) to the
concentration of 5 g/ml and were coated on microtiter plates at 100 l/well (0.5 g per well) to capture
PP-VNHA or PP-HKHA. The bound pseudoparticles were detected by anti-H1 (Abcam) or anti-H5 antibodies
(a generous gift from Robert Webster, St. Jude Children’s Research Hospital) followed by their respective
horseradish peroxidase (HRP)-conjugated secondary antibodies with 3,3=,5,5=-tetramethylbenzidine sub-
strate (Invitrogen).
Viruses. Recombinant PR8 expressing HA and NA derived from either VN1203 (VNHA,NA) or HK5498
(HKHA,NA) was generated as described previously (52). The VNHA,NA virus was a vaccine seed strain, kindly
provided by Robert Webster, with its multibasic HA cleavage site replaced by that of a low-pathogenicity
avian inﬂuenza virus (53). For UV inactivation, inﬂuenza viruses were irradiated with UV light (CL-100 ultra
violet cross-linker) for 15 min.
Preparation of human PBMC-derived macrophages and murine bone marrow-derived macro-
phages. Human PBMC were separated from buffy coats of healthy donors (Hong Kong Red Cross Blood
Transfusion Service) using Ficoll-Paque density gradient (GE Healthcare Life Sciences) under Institutional
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Review Board (IRB) approval (UW 10-124). Monocytes/macrophages were isolated by plastic adherence
and were cultured in complete RPMI medium supplemented with 10% fetal bovine serum (FBS) and 10
ng/ml human M-CSF or GM-CSF (Gibco) for 7 days. Human PBMC-derived dendritic cells were differen-
tiated with 10 ng/ml of IL-4 (Gibco) and 50 ng/ml of GM-CSF for 7 days. The research protocol was
approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong
Kong West Cluster (UW 10-124). For preparation of murine bone marrow-derived macrophages, bone
marrow cells were isolated from femurs and tibias and cultured in RPMI medium supplemented with 10%
FBS and 10 ng/ml of mouse M-CSF (R&D Systems) for 7 days.
CLEC5A gene silencing by siRNA. SmartPool ON-TARGETplus human CLEC5A siRNA (L-021371;
Dharmacon) or ON-TARGETplus nontargeting pool (D-001810; Dharmacon) were transfected into human
PBMC-derived macrophages using HiPerFect (Qiagen). Brieﬂy, 100 M siRNA and 6 l of HiPerFect
reagent (per well) were mixed with RPMI, incubated at room temperature for 15 min, and added to the
cells seeded in 24-well plates. Cells were further incubated at 37°C for 72 h before cell sorting.
Macrophages transfected with CLEC5A gene-speciﬁc siRNAs were sorted using murine anti-human
CLEC5A IgG2b antibody (clone 283834) to acquire the CLEC5A population, while a murine IgG2b
isotype control (clone 133303) antibody was applied to yield the CLEC5A population from the cells
transfected with nontargeting control siRNA for comparison.
Infection and treatment of macrophages. Differentiated human or murine macrophages were
infected with inﬂuenza viruses at an MOI of 2. After 1 h of adsorption, the virus inoculum was removed
and the cells were washed once with phosphate-buffered saline (PBS), followed by incubation with
infection medium (RPMI supplemented with 2% FBS) for 24 h. For Syk inhibition and CLEC5A blocking
assay, human PBMC-derived macrophages were pretreated with the indicated concentrations of Bay
61-3606 (Merck Millipore) or anti-human CLEC5A antagonistic antibody for 1 h before and throughout
the infection process. Supernatant was collected at 24 h posttreatment to measure the cytokines and
chemokines. The 50% cytotoxic concentration (CC50) of Bay 61-3606 in M-CSF-differentiated macro-
phages was 243 M (data not shown). For treatment with TLR ligands, murine bone marrow-derived
macrophages from CLEC5A/ and WT populations were treated with zymosan (10 g/ml), poly(I·C) (50
g/ml), lipopolysaccharide (100 g/ml), or gardiquimod (10 g/ml) for 24 h before the supernatant was
collected.
Quantiﬁcation of cytokines and chemokines. Culture supernatants collected were irradiated with
UV light (CL-100 ultra violet cross-linker) for 15 min to inactivate the viruses. The concentrations of the
cytokines and chemokines in the culture supernatant were quantiﬁed by FlowCytomix (eBioscience), a
multiplex bead-based assay for quantiﬁcation of multiple cytokines and chemokines using ﬂow cytom-
eters. BD FACSCalibur was used for the experiments, and the concentrations of cytokines and chemo-
kines were determined using FlowCytomix Pro 3.0 software.
Quantiﬁcation of viral M gene. RNA was isolated from the infected cells using an RNeasy minikit
(Qiagen, Germany), and cDNA was reverse transcribed by using oligo(dT)20 and the SuperScript ﬁrst-
strand synthesis system (Invitrogen). Quantitative real-time PCR analysis was performed using a Light-
Cycler system SW 3.5.3 (Roche). The following inﬂuenza M-gene primer sequences were used: forward,
5=-CTTCTAACCGAGGTCGAAACG-3=; reverse, 5=-GGCATTTTGGACAAAGCGTCTA-3=.
Animal experiments. The animal experiments were approved by the Committee of the Use of Live
Animals for Teaching and Research of the University of Hong Kong (CULATR 3137-13). The CLEC5A/
population was originally generated by excision of exons 3 to 5 from of the CLEC5A genomic DNA
(encoding exons 1 to 7), isolated from a 129/Sv genomic DNA bacterial artiﬁcial chromosome library
using Cre/loxP-mediated recombination in embryonic stem cells derived from the 129 mouse strain (37),
followed by backcrossing 10 generations in a C57BL/6 background before they were interbred at the
laboratory of Shie-Liang Hsieh at Academia Sinica, Taiwan. The CLEC5A/ and the matching C57BL/6
wild-type mice were imported and bred at the Laboratory Animal Unit (AAALAC accredited since 2005)
at the University of Hong Kong under the same housing conditions. To monitor viral pathogenesis in
CLEC5A/ and the matching C57BL/6 wild-type mice, mice were anesthetized by intraperitoneal
injection of ketamine and xylazine, followed by intranasal inoculation with 4,766 PFU (5 MLD50) or 953.2
PFU (1 MLD50) of VNHA.NA in 25 l minimal essential medium (MEM). Mice were monitored daily and
clinical symptoms and weight recorded on alternate days. Mice were sacriﬁced by intraperitoneal
injection of pentobarbital on days 1, 4, and 7 postinfection, and the lungs were collected and homog-
enized in 1 ml of PBS (Omni tissue homogenizer; Omni International). Viral titers were determined in
MDCK cells by determining the 50% tissue culture infective dose (TCID50), and cytokines or chemokines
were quantiﬁed by the bead-based cytokine quantiﬁcation kit (BD Bioscience).
Flow-cytometric immunophenotyping. The mouse lungs were lavaged twice with 1 ml of ice-cold
RPMI. Red blood cells were lysed, and a small aliquot of the cell suspension was stained with trypan blue,
followed by counting of viable cells under a light microscope; the total viable cell count for each BAL ﬂuid
sample was calculated accordingly. For immunophenotyping of the cells in the BAL ﬂuid, cells were
subjected to Fc receptor blocking (eBioscience) and further stained with antibodies for cell markers (all
from BioLegend) for 30 min on ice. Mixture 1 contained ﬂuorescein isothiocyanate (FITC)-CD11c (N418),
allophycocyanin (APC)-Cy7-CD11b (M1/70), APC-Ly6G (1A8), phycoerythrin (PE)-Cy7-Ly6C (HK1.4), PE-
F4/80 (BM8), and peridinin chlorophyll protein (PerCP)-Cy5.5-MHC-II (I-AE). Mixture 2 contained APC-CD3
(145-2C11), APC-Cy7-CD4 (GK1.5), PerCP-Cy5.5-CD8 (53-6.7), FITC-CD49b (DX5), PE-T cell receptor gamma/
delta (TCR/) (GL3), and PE-Cy7-B220 (RA3-6B2). Cells were classiﬁed based on the following surface
markers: neutrophils (CD11b MHC-IIlo Ly6C Ly6G), alveolar M (F480 MHC-IIhi CD11c Ly6C),
inﬂammatory monocytes (F480 MHC-IIhi CD11c Ly6C), dendritic cells (F480 MHC-IIhi CD11b
CD11c Ly6C), B cells (B220 CD3), CD4 T cells (CD3 CD4 CD8), CD8 T cells (CD3 CD4 CD8),
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 T cells (CD3 TCR), and NK cells (CD49b CD3). Cells were ﬁxed with 4% paraformaldehyde prior
to data acquisition using ﬂow cytometry. The results were analyzed by FlowJo.
Statistical analysis. Statistical signiﬁcance was analyzed using the Mann-Whitney test with a
threshold P value of 0.05 using GraphPad version 6.0 (GraphPad Software). Survival of mice was
compared using log-rank test.
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